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ABSTRACT
Cetuximab, a monoclonal antibody directed against the
epidermal growth factor receptor, has activity against
colorectal cancer. Treatment is associated with skin
toxicity, and the safety of cetuximab in patients with
psoriasis is unknown. We report the case of a male
patient with stage IV colorectal cancer (CRC) and a
life-long history of extensive psoriasis. This patient
experienced a durable remission of his CRC and major
improvement of his psoriasis during single-agent treat-
ment with cetuximab. We conclude that, despite its
known skin toxicity, cetuximab treatment can be of-
fered to colorectal patients suffering from psoriasis.
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1. CASE REPORT
Cetuximab, an immunoglobulin G1 monoclonal anti-
body directed against the human epidermal growth fac-
tor receptor (EGFR), is effective for the treatment of
metastatic colorectal cancer (CRC). Few data on the
safety of cetuximab in patients with pre-existing chronic
skin diseases are available, but here, we report on an
80-year-old man, successfully treated with cetuximab,
who had suffered from extensive treatment-resistant
psoriasis since adolescence. Diverse lifelong treatments
had provided only partial relief. Recently, he had used
calcipotriol ointment up to 4 times weekly.
Our patient underwent resection of a well-differ-
entiated adenocarcinoma (sigmoid, stage III, pT4N1M0)
in June 2003, followed by 8 months of adjuvant che-
motherapy [bolus 5-fluorouracil (5-FU) and leucovorin
(LV)]. In September 2004, bilateral inoperable liver
metastases were treated with capecitabine until April
2005; best response was stable disease. At progres-
sion, second-line treatment was 5-FU/LV/irinotecan
(FOLFIRI) from September 2005 until May 2006,
achieving a partial response. Disease progressed in
August 2006, and LV/5-FU/oxaliplatin (FOLFOX7) was
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administered until December 2007. Disease stabilized
before progressing again.
After a short treatment-free interval, cetuximab
monotherapy (400 mg/m2, intravenously over 2 hours
on day 1, and 250 mg/m2, intravenously over 1 hour
on day 8 and once weekly thereafter) was initiated in
February 2007. Immunohistochemistry for EGFR on
the primary tumour was negative. Over the next 6
weeks, the psoriasis lesions lessened considerably
(Figure 1), and the patient reduced calcipotriol
ointment applications to once weekly.
The main adverse effects of cetuximab are der-
matologic. Grade 2 dermatitis and folliculitis devel-
oped in this patient, but were controlled by topical
clindamycin and then lessened in intensity. On re-evalu-
ation in May 2007, almost complete regression of the
liver metastases and a normalization of blood concen-
trations of carcinogenic embryonic antigen were ob-
served. Throughout this period, no local or systemic
corticosteroids were administered. In September 2007,
irinotecan was added to cetuximab treatment because
of disease progression. Disease control was regained,
and the patient is still receiving cetuximab (July 1, 2008).
He also continues to experience a marked improve-
ment of his psoriasis.
2. DISCUSSION AND CONCLUSIONS
We believe that this is the first case report of the safety
of cetuximab monotherapy in a patient with metastatic
CRC and psoriasis. Trivin et al. 1 reported on a patient
who had both a tumour response and durable remis-
sion of psoriasis after treatment with cetuximab in com-
bination with FOLFIRI. However, that case did not
differentiate between a potential beneficial effect of
the chemotherapy and the effect of the cetuximab.
Durable remissions of psoriasis have also been
reported in patients undergoing high-dose chemotherapy
for hematologic malignancies 2–4.
We conclude that a previous history of psoriasis or
active lesions should not be regarded as a contraindi-
cation for cetuximab treatment in patients with ad-
vanced CRC. Psoriasis is associated with abnormalNEYNS et al.
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FIGURE 1 Tumour response and resolution of psoriasis in a patient
with metastatic colorectal cancer (CRC) treated with cetuximab
monotherapy. An 80-year-old man was treated with cetuximab third-
line for metastatic CRC. His psoriasis on lower limbs, elbows, forearms,
trunk, and face diminished in intensity after 6 weeks of treatment.
This improvement was accompanied by almost complete regression
of liver metastases. (A,C) February 2007. (B,D) May 2007.
expression of EGFR in the involved skin 5. It is possible
that cetuximab may induce remission of psoriasis
through regulation of this abnormal EGFR metabolism.
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